Compare IRMD & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | CRMD |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 910.4M | 943.9M |
| IPO Year | 2014 | 2010 |
| Metric | IRMD | CRMD |
|---|---|---|
| Price | $97.27 | $12.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $72.00 | $17.43 |
| AVG Volume (30 Days) | 80.6K | ★ 2.6M |
| Earning Date | 02-12-2026 | 11-12-2025 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 13.00 | N/A |
| EPS | 1.65 | ★ 2.25 |
| Revenue | $80,511,268.00 | ★ $214,303,672.00 |
| Revenue This Year | $15.17 | $627.89 |
| Revenue Next Year | $10.15 | $40.95 |
| P/E Ratio | $58.83 | ★ $5.41 |
| Revenue Growth | 12.91 | ★ 1647.67 |
| 52 Week Low | $47.48 | $5.60 |
| 52 Week High | $98.44 | $17.43 |
| Indicator | IRMD | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 65.84 | 63.43 |
| Support Level | $90.92 | $11.78 |
| Resistance Level | $98.24 | $12.51 |
| Average True Range (ATR) | 2.55 | 0.51 |
| MACD | -0.43 | 0.13 |
| Stochastic Oscillator | 81.65 | 85.18 |
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.